Bharat Biotechs Covaxin Gets SEC Approval On Its Phase 3 Trials Efficacy Data

The Subject Expert Committee (SEC) has approved the Phase -3 trial data of Bharat Biotech's Covaxin that was conducted on 25,800 subjects.The data on India's only homegrown Covid-19 vaccine has shown 77.8% efficacy.Earlier this month, Bharat Biotech had said phase 3 data will first be submitted to the Central Drugs Standard Control Organisation and then to peer-reviewed journals. It also said it was conducting phase 4 trials to check the “real-world effectiveness of the vaccines” and to meet scientifically approved standards for safety and efficacy.The Hyderabad-based vaccine maker will also hold a ‘pre-submission’ meeting on Wednesday with the World Health Organization, regarding the approval for Covaxin. A pre-submission meeting will provide an opportunity to the company to receive advice and guidance before submission of the final dossier, as well as an opportunity to meet WHO assessors who will be involved in examining their product.In May, Bharat Biotech said an emergency use listing (EUL) application had been submitted to WHO, with regulatory approvals expected between July and September. The EUL pathway involves a rigorous assessment of clinical trial data — as well as additional data on safety, efficacy and quality — and a risk management plan.An emergency approval from WHO will allow Bharat Biotech to export vaccines and enable easy international travel of Indian citizens who have been administered Covaxin.Covaxin is an inactivated vaccine developed by chemically treating novel coronavirus samples to make them incapable of reproduction. This process leaves viral proteins, including the spike protein of the coronavirus which it uses to enter the human cells, intact.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!